FY2027 EPS Estimates for BioRestorative Therapies, Inc. (NASDAQ:BRTX) Lowered by Roth CapitalZolmax • 29 days ago
BioRestorative Therapies, Inc. (NASDAQ:BRTX - Free Report) - Research analysts at Roth Capital reduced their FY2027 EPS estimates for shares of BioRestorative Therapies in a report issued on...
Share to Feed
BioRestorative Therapies ( NASDAQ:BRTX ) Full Year 2023 Results Key Financial Results Net loss: US$14.4m (loss narrowed...
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ( BioRestorative , BRTX or the...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
BRTX stock results show that BioRestorative Therapies beat analyst estimates for earnings per share and beat on revenue for the fourth...
MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ( BioRestorative , BRTX or the Company ) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies, Inc. (NASDAQ:BRTX - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 19,900...
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ( BioRestorative or the Company ) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies...
BioRestorative Therapies, Inc. (NASDAQ:BRTX Free Report) Investment analysts at Roth Capital lifted their FY2023 EPS estimates for BioRestorative Therapies in a research note issued...
MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQ:BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease...
BioRestorative Therapies (BRTX) has released an update to notify the public and investors about a regulation fd disclosure. The information detaile...